Immune response to ARCT-2303 and adjuvanted influenza vaccine

The term "Immune response to ARCT-2303 and adjuvanted influenza vaccine" refers to the physiological process and clinical evaluation of immunity generated by the concurrent administration of two distinct vaccines. ARCT-2303 is a self-amplifying mRNA (sa-mRNA) vaccine candidate developed by Arcturus Therapeutics that targets the SARS-CoV-2 spike protein, utilizing the STARR platform to provide prolonged antigen expression at lower doses compared to conventional mRNA vaccines (Arcturus Therapeutics, 2023). Adjuvanted influenza vaccines, such as those containing the MF59 oil-in-water emulsion, are designed to enhance immunogenicity against seasonal flu by stimulating a broader and more persistent immune response, particularly in older populations (CDC, 2023). This entry does not describe a single molecular target like a receptor or enzyme, but rather a complex biological outcome involving the activation of the innate and adaptive immune systems. Clinical trials, such as NCT05822544, evaluate the safety and immunogenicity of this combination to ensure that co-administration does not lead to immune interference or excessive reactogenicity (ClinicalTrials.gov, 2023). Understanding this response is critical for public health strategies involving seasonal co-vaccination and the development of next-generation vaccine platforms.

Other names

ARCT-2303 and influenza vaccine co-administrationsa-mRNA COVID-19 and adjuvanted flu vaccine responseNCT05822544

ARCT-2303 utilizes self-amplifying mRNA to express the SARS-CoV-2 spike protein within host cells, while adjuvanted influenza vaccines deliver viral hemagglutinin antigens alongside an adjuvant to enhance antigen presentation and cytokine production.